Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;17(5):1552-1569.
doi: 10.1007/s12015-021-10139-5. Epub 2021 Mar 5.

Mesenchymal Stem Cell-Based Therapy for Diabetes Mellitus: Enhancement Strategies and Future Perspectives

Affiliations
Review

Mesenchymal Stem Cell-Based Therapy for Diabetes Mellitus: Enhancement Strategies and Future Perspectives

Haisen Li et al. Stem Cell Rev Rep. 2021 Oct.

Abstract

Diabetes mellitus (DM), a chronic disorder of carbohydrate metabolism, is characterized by the unbridled hyperglycemia resulted from the impaired ability of the body to either produce or respond to insulin. As a cell-based regenerative therapy, mesenchymal stem cells (MSCs) hold immense potency for curing DM duo to their easy isolation, multi-differentiation potential, and immunomodulatory property. However, despite the promising efficacy in pre-clinical animal models, naive MSC administration fails to exhibit clinically satisfactory therapeutic outcomes, which varies greatly among individuals with DM. Recently, numbers of innovative strategies have been applied to improve MSC-based therapy. Preconditioning, genetic modification, combination therapy and exosome application are representative strategies to maximize the therapeutic benefits of MSCs. Therefore, in this review, we summarize recent advancements in mechanistic studies of MSCs-based treatment for DM, and mainly focus on the novel approaches aiming to improve the anti-diabetic potentials of naive MSCs. Additionally, the potential directions of MSCs-based therapy for DM are also proposed at a glance.

Keywords: Combination therapy; Diabetes mellitus; Exosome; Genetic modification; Mesenchymal stem cells; Preconditioning.

PubMed Disclaimer

References

    1. Kamal, M. M., & Kassem, D. H. (2020). Therapeutic potential of Wharton’s jelly mesenchymal stem cells for diabetes: Achievements and challenges. Frontiers in Cell and Developmental Biology, 8, 16. - PubMed - PMC - DOI
    1. Donzelli, E., & Scuteri, A. (2020). Mesenchymal stem cells: A trump card for the treatment of diabetes? Biomedicines, 8(5), 112. - PMC - DOI
    1. Grohová, A., Dáňová, K., Špíšek, R., & Palová-Jelínková, L. (2019). Cell based therapy for type 1 diabetes: Should we take hyperglycemia into account? Frontiers in Immunology, 10, 79. - PubMed - PMC - DOI
    1. Qi, Y., Ma, J., Li, S., & Liu, W. (2019). Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes. Stem Cell Research & Therapy, 10(1), 274. - DOI
    1. Keane, K. N., Calton, E. K., Carlessi, R., Hart, P. H., & Newsholme, P. (2017). The bioenergetics of inflammation: Insights into obesity and type 2 diabetes. European Journal of Clinical Nutrition, 71(7), 904–912. - PubMed - DOI - PMC

Publication types

LinkOut - more resources